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Introduction: Fusion genes can be formed as the result of chromosomal 
translocations, deletions or inversions. Recent developments in sequencing 
techniques and bioinformatics analysis enable researchers to identify and 
validate novel fusion genes using paired-end RNA sequencing on primary tumor 
material. The aim of this pilot study is to improve selection of predicted of high 
confidence fusion genes for follow-up studies 
Materials and methods: RNA was isolated from a frozen lung tumor biopsy of a 
patient with an adenocarcinoma and subjected to paired-end RNA sequencing. 
Reads were mapped to the reference genome (hg19) and potential fusion genes 
were called using a fusion prediction tool (deFuse). After applying different 
filtering steps and manual inspection of the reads using the IGV and the UCSC 
browser, selected high confidence fusion genes were validated by RT-PCR. 
Results: Eighty-five potential fusion genes were called by deFuse. Of these, 18 
had a probability of ≥0.95 and 67 had probability <0.95. A further selection of the 
18 potentially fusion genes was achieved by excluding predicted fusion genes 
that were likely to be the result of read-through transcripts of adjacent genes 
(n=7). Manual inspection of the remaining 11 candidates resulted in a further 
exclusion of 2 predicted fusion genes, based on lack of split reads and mapping to 
an intergenic region, respectively. Three of the 9 remaining fusion genes involved 
the same two genes, i.e. SCNN1A and TNFRSF1A, but with different breakpoints. 
Four fusion genes contained a predicted open reading frame (ORF) and were 
validated by RT-PCR. RT-PCR validation of SCNN1A and TNFRSF1A using a primer 
set flanking the three breakpoint regions did yield the expected bands in the 
tumor sample, but also revealed PCR products in a normal control sample. These 
predicted fusion genes could have been excluded by an additional filtering step, 
i.e. removal of fusion genes located in expressed sequence tag (EST) enriched 
regions. The other three predicted fusion genes did yield the expected bands in 
the tumor samples and were validated by Sanger sequencing. No PCR products 
were observed in the normal control sample. This indicated that these three 
predictions most likely present true gene fusions. 
Conclusion: The application and validation of the deFuse fusion gene detection 
software in a lung cancer specimen is improved by inspection of the resulting 
fusions for read-through variants, ESTs and spanning reads. 
 






Fusion genes are the result of genomic rearrangements that occur due to 
incorrect DNA repair caused by errors in the DNA repair machinery1-2. A number 
of fusion gene products have been shown to be causally involved in a variety of 
diseases such as hematological malignancies and childhood sarcomas2-3. Fusion 
genes were detected mainly in leukemia and sarcoma, and appeared to be less 
common in solid tumors, such as lung cancer. The Philadelphia chromosome was 
the first identified translocation and is a classical example of a specific gene 
fusion, i.e. BCR-ABL1, in a human neoplasia4. It was discovered in chronic 
myelogenous leukemia (CML) and plays an important role in tumor cell survival 
through inhibition of apoptosis4-5.  
In B-cell lymphoma, many characteristic chromosomal translocations have 
been identified, but unlike leukemia and sarcoma, these translocations do not 
result in fusion genes. Instead these B-cell lymphoma-specific translocations 
result in overexpression of the target gene due to juxtaposition of the gene to a 
genomic region that contains strong enhancers, such as the immunoglobulin 
heavy and light gene enhancers. An example is the chromosomal translocation in 
Burkitt lymphoma, which places the MYC proto-oncogene under control of the 
immunoglobulin (Ig) heavy or light chain gene enhancers2, 6. The MYC 
translocation results in transcriptional activation of the MYC oncogene by Ig 
regulatory elements2.  
In solid tumors, the presence of fusion genes remained undetected until 
recently. EML4-ALK was the first fusion gene to be discovered in non-small cell 
lung cancer7 with a prevalence of around 3-6%8. Recurrent fusion genes may 
represent potential treatment targets as the tumor cells are often dependent on 
signaling cascades activated by the fusion products for growth and survival9. This 
dependency is referred to as “oncogene addiction”10. These driver genes are 
often kinases and they represent novel therapeutic targets for the treatment of 
lung cancer. Targeted treatment is already available for several of these fusion 
products. An example is crizotinib for EML4-ALK in NSCLC patients11. In phase I 
and II clinical trials12-13, lung cancer patients harboring ROS1 and RET 
translocations showed good responses to crizotinib and cabozantinib, 
respectively. 
Developments in sequencing technologies have created high throughput 




approaches14-16. Transcriptome sequencing allows quantification of gene 
expression, identification of splice variants, identification of 5’ and 3’ ends of 
transcripts, detection of novel transcripts and discovery of novel fusion 
products17-18. Comprehensive genome and transcriptome sequencing in 
combination with the development of new algorithms has resulted in the 
identification of several novel fusion genes19-20.  
We used deFuse, a computational algorithm for discovery of fusion 
transcripts on paired-end whole transcriptome sequencing data. Information 
from split reads (reads that cover the fusion boundary) and discordant reads 
(mate pair reads that map to two distinct genomic regions) are used for 
prediction of fusion transcripts. DeFuse generates multiple confidence measures 
to estimate the probability of the predicted fusions and predicts the presence of 
an ORF in the fusion products9. The aim of this chapter is to explore the 
significance and relevance of the criteria generated by deFuse to select true gene 
fusions and potentially identify novel fusion genes in a lung cancer sample.  
 
Materials and Methods 
 
Patient 
 A Fresh frozen tissue sample was obtained from a lung adenocarcinoma patient. A 
normal lung tissue sample was used as a negative control for validation by RT-PCR. 
Written informed consent was obtained from the patient. 
 
RNA isolation 
Total RNA was isolated using TRIzol following the standard protocol provided 
by the manufacturer (Life technologies, Carlsbad, USA). The concentration of the 
RNA samples was measured on a NanoDrop (Thermo Fisher Scientific Inc., 
Waltham, USA). 
 
Transcriptome sequencing and fusion detection 
The truSeq RNA kit (Illumina, San Diego, USA) was used to prepare the library 
for paired-end RNA sequencing starting with 500ng of RNA. Paired-end reads of 
100nt were produced on the Hiseq2500 (Illumina, San Diego, USA). Reads were 
mapped to the reference genome using deFuse (v.0.6.1) to predict fusion 
transcripts9. DeFuse aligns the reads through an automated process which 
incorporates SAMtools21, bowtie22, BLAT23 and GMAP24. 
 





DeFuse can generate several confidence measures such as number of split 
and spanning reads, EST island adjusted percent identity score, genome adjusted 
percent identity score, split-span p-value, a probability score and some other 
confidence scores. These scores can be used to identify the most likely fusion 
gene candidates. Besides these criteria included within the deFuse output file, 
the split read sequence identified by deFuse can be checked manually using a 
custom track on IGV. Moreover, correct mapping of the sequence of the 
predicted fusion candidates has been confirmed using the University of California 
Santa Cruz (UCSC) genome browser.  
Based on the initial evaluation of different confidence scores, the optimised 
filtering steps applied included: probability score ≥0.95; not being derived 
from read-through products according to deFuse; reliable split and spanning 
reads using a custom track on IGV25; not  originating from intergenic regions or 
read-through transcripts according to the mapping of the fusion gene sequence 
to the UCSC genome browser. 
 
Validation of the fusion products by RT-PCR 
cDNA was synthesized with Superscript II reverse transcriptase and random 
primers according to the manufacturer’s protocol using 500ng of total RNA 
(Invitrogen, Carlsbad, USA). PCR was performed using 10ng cDNA as input in a 
final volume of 30µl containing 1x PCR buffer, 0.2µl Tag DNA polymerase 
(5unit/μl), MgCl2 (final concentration 1.5mM) (Invitrogen, Carlsbad, USA) and 
500nM primers designed using Clone Manager Suite (Sci-Ed Software, Morrisville, 
USA) (Table 1). Amplification was for 35 cycles using a thermocycler (Bio-Rad, 
Hercules, USA). PCR products were analyzed on a 1% agarose gel. Gel pictures 
were captured using Gel Doc XR+ System (Bio-Rad, Hercules, USA). PCR products 
were purified using Zymoclean™ Gel DNA Recovery Kit (Zymo research, Irvine, 
USA) and sequenced at LGC Genomics (Berlin, Germany). TOPO® TA Cloning® Kit 
(Invitrogen, Carlsbad, USA) was used to clone the SLC10A7-TTC29 fusion product 
according to the manufacturer’s protocol. Five independent colonies with the 









Table 1: RT-PCR primer sets for validation of 4 gene fusions with a predicted ORF. 
Name Primer sequence 
Annealing 
(°C) 
Expected product size 
(bp) 






















RNA sequencing and fusion prediction 
Paired-end RNA sequencing of pulmonary adenocarcinoma resulted in more 
than 42 million reads of which over 25 million reads were on target. Eighty-five 
fusions were predicted in the lung tumor sample by deFuse using the standard 
settings. Of these, 67 had a probability of <0.95 genes, whereas 18 had a 
probability of ≥0.95 (Figure 1).  
As a quality check we first investigated a number of predicted fusions with a 
probability of less than 0.95. Manual inspection of these 67 fusion genes using 
our custom-made track in IGV indicated lack of split and spanning reads for 18 of 
them. Therefore, these were unlikely to represent true fusion transcripts. A 
further manual Inspection on UCSC genome browser revealed that 21 of the 
fusion genes mapped to intergenic regions and 9 fusion products appeared to be 
a read-through. Based on these results, we decided not to inspect the remaining 
19 predicted fusion genes with a probability of <0.95. During this process we 
noticed that several of the false positive predictions could have been excluded 
based on the prediction by deFuse as being a read-through transcript. Examples 
of read-through and intergenic fusion products, as well as fusion products with 
sufficient and insufficient split reads are shown in Figure 2. 
 
 





Figure 1: Diagram shows the results of the deFuse filtering and manual inspection steps. Left wing 
(red) shows results of the initial inspection of the fusions with probability <0.95. Based on these 
analysis we concluded that the probability score was a good first criterion to exclude false positive 
predictions. Moreover, we noticed that a second filtering criterion indicated by the deFuse 
algorithm, i.e. prediction for being a read-through transcript, can correctly remove additional 
unlikely fusion gene candidates. This second criterion was implemented in the right wing (blue) of 






Figure 2: Example of a high confidence fusion and two false positive gene fusions. A) Snapshot of 
STYXL1-TMEM120A on the UCSC browser that shows a read-through transcript. Green arrow shows 
the transcript predicted as fusion by deFuse. B) Snapshot of LINC00267-TRAF5 fusion on the UCSC 
genome browser showing the sequence (red arrow) which had been annotated as being part of the 
TRAF5 gene, but actually maps to an intergenic region in close proximity to this gene (Red arrow). 
Green arrow shows the sequence that was correctly annotated as the LINC00267 gene. C) Snapshot 
of IGV of RAB35-ATP2A2 fusion with sufficient split reads covering fusion boundary. Mixed red and 
blue area shows paired end reads generated by RNA sequencing. The line in the middle indicates 
fusion boundary. D) Snapshot of IGV for a predicted fusion (GRAMD4-CERK) with insufficient split 
reads covering fusion boundary is an indicative of a false positive gene fusion.  




Based on the above described quality check, we used deFuse read-through 
prediction as a second filter for predicted fusion genes in addition to the 
probability score of ≥0.95. Seven of the 18 fusion genes were excluded based on 
this criterion. Inspection of the paired-end reads of the remaining 11 fusion genes 
using IGV in combination with the custom-made track of the sequence of the 
predicted breakpoint fusion regions, indicated lack of reliable split and spanning 
reads for one predicted fusion gene. This fusion was also excluded from further 
analysis. A further quality check of the remaining fusions using the UCSC genome 
browser revealed that one predicted fusion mapped to an intergenic region, 
which was incorrectly annotated as being the more upstream gene by deFuse. 
This predicted gene fusion was also excluded. Three of the remaining 9 predicted 
gene fusions involved the same two genes, i.e. SCNN1A and TNFRSF1A, but with 
different breakpoints (Figure 3A), for the other six, i.e. RAB35-ATP2A2, STAB2-
NUAK1, SLC10A7-TTC29, KMT2B-AC002115.9, PIAS1-SLC24A6 and ZNF827-
ARHGAP10, one breakpoint region was observed for each gene. Validation 
experiments were performed only for the four gene fusions with an ORF as 






Figure 3: Schematic representation of fusion gene products and validation of four fusion products 
with a predicted ORF using RT-PCR. A) Schematic picture of two genes involved in the predicted 
SCNN1A-TNFRSF1A fusion gene transcript and their orientation in the genome. Red bars show 
different breakpoints detected by RNA-seq. Position of the primers are shown in the picture. B) 
Validation of SCNN1A-TNFRSF1A fusion transcript by RT-PCR. The three fusion products were 
detected in both the tumor as well as in the normal sample. C) Two gene fusions (RAB35-ATP2A2 
and STAB2-NUAK1) clustered in an approximately 18Mb region on chromosome 12. Both fusions 
were result of an inversion. D) Schematic picture of SLC10A7-TTC29 gene fusion which was result of 
an eversion. E) Validation of RAB35-ATP2A2, STAB2-NUAK1 and SLC10A7-TTC29 fusion product in 
tumor cDNA by RT-PCR. 




Validation of fusion genes with predicted ORF by RT-PCR 
Four fusion genes (SCNN1A-TNFRSF1A, RAB35-ATP2A2, STAB2-NUAK1 and 
SLC10A7-TTC29) were validated by RT-PCR. Based on different breakpoints 
detected by RNA-seq and the different splice variants of TNFRSF1A, a range of 
fusion products for the predicted SCNN1A-TNFRSF1A fusion gene was expected 
(Figure 3B). PCR products within the expected range were indeed confirmed in 
the tumor sample, but a similar pattern was observed in a normal control lung 
sample, indicative of a false positive fusion prediction. These fusion products 
were probably derived from read-through transcripts, which had been missed in 
the initial manual inspection. The fusion product was derived after splicing of the 
intergenic region between exon 11 of the SCNN1A gene and exon 2 of the 
TNFRSF1A gene. 
Two fusion products, i.e. STAB2-NUAK1 and RAB35-ATP2A2, were confined 
to a region of approximately 18 megabases (Mb) on chromosome 12 and 
involved four genes (Figure 3C). Both fusion products were the result of an 
inversion. In one of the fusion products exon 18 of the STAB2 gene was fused to 
exon 2 of the NUAK1 gene. In the second fusion product exon 2 of the RAB35 
gene was fused to exon 6 of the ATP2A2 gene. The fourth fusion, i.e. SLC10A7-
TTC29, was the result of an eversion in which exon 6 of the SLC10A7 gene was 
fused to exon 10 of the TTC29 gene (Figure 3D). The expected PCR product sizes 
for all of these fusion genes were identified in the tumor samples and not in the 
normal sample, suggesting that they are true fusion genes (Figure 3E). Sanger 
sequencing of the RT-PCR products of these three fusions confirmed the fusion 




Protein fusion products can act as oncogenic drivers in human cancers3-4, 7, 26. 
DeFuse is a computational algorithm that predicts fusion transcripts from paired-
end RNA sequencing data. Here, we aimed to improve selection procedure of 
predicted fusion genes to allow a more optimal selection of high confidence 
fusions for further follow-up studies. 
A high number of false positive predicted fusion genes involved a gene locus 
and a second sequence fragment that actually mapped to an intergenic region. 
These intergenic sequences were annotated to the closest neighboring gene by 




caused by allowing deFuse to call gene fusions in intergenic regions to decrease 
the chance of missing potential fusions9. It seems that this feature can generate a 
lot of false positive fusion gene predictions and might not be optimal in the 
search for genuine novel fusion products. Restricting calling of gene fusions to 
regions within the boundaries of known exons would obviously decrease the 
number of false positives, but might result in loss of true fusion genes.  The 
probability of being true fusion genes based on the data generated by deFuse 
appears to be an efficient primary filter to eliminate most of the false positives. In 
addition, the IGV check using the custom track with the sequences of the 
breakpoint regions of all predicted fusion genes was a valuable tool to exclude 
additional falsely predicted gene fusions. 
We found several read-through transcripts in our data. Some of these 
transcripts had been identified already as read-through by the deFuse program, 
while some others were noted during manual check using UCSC browser or after 
validation by RT-PCR. These fusion transcripts are the result of a mechanism 
called “intergenic splicing”27. These fusions are also referred to as transcription-
induced chimeras or read-through sequences. Read-through transcripts are 
probably generated when transcription fails to stop at the end of a gene locus 
and continues until the termination site of the next adjacent gene28-29. Read-
through sequences usually contain exons of adjacent genes27. Overall, excluding 
read-through transcripts in combination with manual check using IGV on a 
custom made track and the UCSC browser is an efficient approach to exclude 
false positive fusions. 
In recent years, a number of computational methods have been developed 
for the detection of fusion transcripts9, 30-34. These methods show high sensitivity 
for detecting artifacts that can be induced by experimental procedures during 
library preparation and amplification steps prior to RNA sequencing27. Thus, 
selection of alignment software for the detection of fusions and being aware of 
the type of filters they utilize to remove false positive predictions is important. In 
addition, close distance (for example <50Kb) between two adjacent genes might 
be a good sign to consider a transcript as a potential read-through. All together, 
increasing the specificity can reduce the sensitivity of the method and vice versa. 
Therefore, we are always on the edge of adding a false positive or missing a true 
fusion transcript in this type of analysis. Manual check for the selected fusions for 
validation remains crucial to exclude false positives. 




The presence of SCNN1A-TNFRSF1A fusion PCR products in a normal sample 
indicated that this prediction was not valid. So, both deFuse and manual 
inspection using UCSC genome browser did not identify this predicted fusion 
gene as being the result of a read-though transcript. This indicates that an 
additional filtering step should be applied. Therefore, we added an additional 
filter that could remove predicted fusions that map to EST regions with a 
probability ≥0.95. Applying this filter resulted in elimination of the SCNN1A-
TNFRSF1A fusion, without affecting calling of true fusion gene predictions. 
Following this strategy we were able to reliably distinguish true gene fusions from 
false positive ones (Figure 4).    
 
 
Figure 4: Proposed filtering steps to remove false positive gene fusion predictions by 
deFuse. 
 
In conclusion, we set up a step-wise approach to select fusion genes with 
high confidence based on an initial calling made by deFuse and adding additional 
custom selection steps using the IGV in combination with a custom made track 
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